Teva and Apotex prevail in sleep drug dispute
The dispute centred on a treatment that helps people adjust their circadian rhythm | Path now clear for generic drug makers to unveil biosimilar versions of the drug.
Amgen secures five-year ban on psoriasis drug copycat
Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Abbvie seeks to block copycat of endometriosis drug
Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug
Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.
Exelixis takes Cipla to court over generic cancer drug
Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.
Edwards Lifesciences revives Fintiv challenge
Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.
FTC targets ‘Pharma Bro’ Martin Shkreli over start-up
Commission holds that the convicted former pharma head may have violated his life-long ban from working in the life sciences industry | Shkreli is already convicted of conspiring to illegally increase the price of a life-saving drug.
Jazz Pharma’s medical cannabis unit seeks to block generic
UK-based cannabidiol lab sues firms behind proposed ANDA | Feud centres on a cannabis treatment for epilepsy.
Third Circuit backs pharma firm in antitrust clash
Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.
Voluntary licensing opens up HIV treatment to 100 countries
Medicines Patent Pool deals have given 20 million people access to HIV treatment | Full list of sub-licensees.